Lombard Odier Asset Management (Switzerland) Sa Regeneron Pharmaceuticals, Inc. Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $110,919 - $134,796	163 Added 11.11%	1,630 $1.34 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $424,239 - $460,600	601 Added 69.4%	1,467 $1.06 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $276,653 - $349,122	-482 Reduced 35.76%	866 $597,000
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $739,175 - $995,956	1,348 New	1,348 $797,000
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $594,524 - $697,731	-999 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $542,936 - $670,299	999 New	999 $631,000
Q3 2021 Nov 12, 2021	SELL	$574.03 - $680.96 $666,448 - $790,594	-1,161 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$472.8 - $558.54 $62,882 - $74,285	-133 Reduced 10.28%	1,161 $648,000
Q1 2021 May 17, 2021	BUY	$446.73 - $548.2 $578,068 - $709,370	1,294 New	1,294 $612,000
Q4 2020 Feb 16, 2021	SELL	$478.3 - $607.98 $1.4 Million - $1.78 Million	-2,933 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$544.75 - $658.21 $1.6 Million - $1.93 Million	2,933 New	2,933 $1.64 Million
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $1.29 Million - $1.69 Million	-2,625 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$336.18 - $494.43 $882,472 - $1.3 Million	2,625 New	2,625 $1.28 Million
Q3 2019 Nov 14, 2019	SELL	$273.46 - $318.39 $356,865 - $415,498	-1,305 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$372.08 - $439.57 $485,564 - $573,638	1,305 New	1,305 $536,000

Others Institutions Holding REGN

# of Institutions

1,484

Shares Held

83.7M

Call Options Held

1.22M

Put Options Held

1.5M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account